ClinicalTrials.Veeva

Menu

A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 1

Conditions

Alzheimer's Disease

Treatments

Drug: MK-1708
Drug: Itraconazole

Study type

Interventional

Funder types

Industry

Identifiers

NCT06586606
MK-1708-003 (Other Identifier)
1708-003

Details and patient eligibility

About

The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.

Enrollment

12 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a body mass index (BMI) ≥18.5 and ≤32 kg/m^2, inclusive

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

  • Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

12 participants in 2 patient groups

Period 1: MK-1708
Experimental group
Description:
Participants will receive a single oral dose of MK-1708 on Day 1.
Treatment:
Drug: MK-1708
Period 2: MK-1708 and Itraconazole
Experimental group
Description:
A washout period of at least 10 days will occur between MK-1708 dosing in Period 1 and the first itraconazole dosing in Period 2. In Period 2, participants will receive itraconazole twice daily on Day 1 and once daily on Days 2 through Day 19. Participants will also receive a single oral dose of MK-1708 on Day 4.
Treatment:
Drug: Itraconazole
Drug: MK-1708

Trial contacts and locations

1

Loading...

Central trial contact

Toll Free Number

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems